CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C. Wainwright Genetic Medicines Virtual Conference 2025 : Fireside chat will be available to view on demand beginning Tuesday, October... Read More

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Citi’s 2025 Biopharma Back to School Conference : Fireside chat on Tuesday, September 2, 2025, at 4:45 p.m. ET in Boston, MA.... Read More

Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset Completed follow-on offering, raising $144.2 million in gross proceeds and extending cash runway into 2027 Secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to advance... Read More

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common... Read More

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc . (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with... Read More

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%)... Read More

Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation Multiple hotspot Prime Editors may benefit more than 93% of people with CF CAMBRIDGE, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to... Read More

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Jefferies Global Healthcare Conference : Fireside chat on Thursday, June 5, 2025, at 10:30 a.m. ET in New York, NY. Goldman Sachs... Read More

Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of... Read More

First ever clinical data supporting safety and efficacy of Prime Editing in humans Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative Rapid engraftment observed in both neutrophils and platelets Encouraging safety profile; no serious adverse events related to PM359 Initiating efforts... Read More

Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative... Read More

Prime Editing has potential to be best-in-class approach for AATD Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP High levels of editing at the target site in preclinical studies with full restoration of circulating wild-type AAT protein (M-AAT) to normal human range Expects to file IND and/or CTA in mid-2026 CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE)... Read More

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 Additional high-value programs advancing through preclinical development CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of... Read More

CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at... Read More

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at... Read More

Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone payments On track... Read More

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Guggenheim's Inaugural Healthcare Innovation Conference : Fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in... Read More

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND and/or CTA filing expected in 1H 2026 CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a... Read More

On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and... Read More

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson’s Disease Program Toward Expected IND Application and/or CTA in 1H 2026 Today Announced Strategic Research Collaboration and License Agreement with... Read More

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies Prime Medicine to Receive $110 Million Upfront, with Potential for More Than $3.5 Billion in Milestones, Including $1.4 Billion in Development Milestones and More Than $2.1 Billion in Commercialization Milestones CAMBRIDGE, Mass., Sept.... Read More

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Morgan Stanley 22 nd Annual Global Healthcare Conference : Fireside chat on Wednesday, September 4, 2024, at 1:05 p.m. ET in New... Read More

CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc . (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “In the second quarter, we achieved a key milestone for Prime Medicine and our next-generation gene editing... Read More

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences: Jefferies Healthcare Conference: Fireside chat on Wednesday, June 5, 2024, at 1:30 p.m.... Read More

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at... Read More

Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 Presented new preclinical data demonstrating broad potential of Prime Editing technology at LNP Formulation and Process Development Summit and ASGCT 2024 Appointed Tony Coles, M.D. as senior advisor CAMBRIDGE, Mass., May 10, 2024 (GLOBE... Read More

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new... Read More

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a panel discussion at the 27 th Annual Milken Institute Global Conference entitled “Things That Will... Read More

First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that the... Read More

Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc.... Read More

Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 Progressing broader portfolio across core areas of focus; expect to initiate IND-enabling activities in first liver and ocular disease programs in 2024 Advancing hotspot and PASSIGE™ Prime Editors for CF following entry into therapeutic development agreement with Cystic Fibrosis Foundation... Read More

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: TD Cowen 44 th Annual Healthcare Conference: Keith Gottesdiener, M.D., President and Chief Executive Officer, will participate in a panel... Read More

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its... Read More

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded... Read More

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional... Read More

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday,... Read More

CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF). CF is an... Read More

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr.... Read More

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at... Read More

Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today announced that company management will present at two upcoming investor conferences: Stifel Healthcare Conference : Fireside Chat by Keith Gottesdiener, M.D., President and Chief Executive Officer, on Tuesday,... Read More

Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile Received U.S. FDA Rare Pediatric Drug... Read More

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated Threshold Necessary to Reverse Disease Manifestations Up to 56% Whole Liver Editing Observed in Humanized GSD1b Mouse Model No Detectable Off-target Edits Observed Following Comprehensive in vitro Analysis Data Presented Today in... Read More

New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RHO p.P23H Mutation and up to 65% at RHO p.V345L and p.P347L, Well Above Threshold Required to Stop Disease Progression in Photoreceptors No Detectable AAV Genome Integration and No Detectable Off-target Edits Observed Data... Read More

CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the Company will showcase advances in preclinical data across the Prime Editing pipeline and platform at several healthcare industry conferences in October and November 2023. “We are pleased to share new... Read More

Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences: BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome... Read More

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two upcoming investor conferences. 2023 Wells Fargo Healthcare Conference: Fireside chat on Thursday,... Read More

Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio’s shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing Cash, cash equivalents, investments and restricted... Read More

Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (HSC) transplant and in vivo genetic therapies CAMBRIDGE, Mass. and BASEL, Switzerland, June 22, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc.... Read More

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in three investor conferences in June: Jefferies Healthcare Conference: Fireside chat on Wednesday, June... Read More

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at two virtual investor conferences in May: Barclays 2023 Gene Editing & Gene Therapy Summit: Fireside chat... Read More

Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359 New preclinical data highlighted ability of PASSIGE™ platform to generate multiplex-edited CAR-T cells without using viruses CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a... Read More

New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting Expanded Board of Directors with appointment of Jeff Marrazzo, former CEO of Spark Therapeutics Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine’s second patent, No. 11,643,652, and... Read More

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days on... Read More

Announced preclinical data providing further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function, as well as new preliminary safety analyses demonstrating no detected off-target activity Nominated PM359, first development candidate for the treatment of Chronic Granulomatous Disease (CGD) Successfully completed upsized initial public offering, raising $199 million in gross proceeds... Read More

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023 at 9:50 a.m.... Read More

New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson’s disease cells New data leveraging PASSIGE technology demonstrated ability to integrate kilobase-sized DNA in human T cells Additional LNP and AAV delivery... Read More